Skip to content

Study · Randomized controlled trial · 2004

5 results

Luteal phase defects following agonist-triggered ovulation: a patient-dependent response.

Emperaire JC, Parneix I, Ruffie A

Reproductive biomedicine online1 Jul 2004Cited by 26 (Europe PMC)

PMID15257812 (opens in a new tab)DOI10.1016/s1472-6483(10)62105-0 (opens in a new tab)PepBankPUB-15257812
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with defective luteal phases, increased or repeated triptorelin doses did not restore the luteal phase.

    In plain wordsIn patients with defective luteal phases, increased or repeated triptorelin doses did not restore the luteal phase.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeLuteal phase restoration
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.5 mg once or 0.1 mg three timesAs given in this study (human).

    Source sentences

    Summary
    In defective LP patients, increasing or repeating triptorelin doses did not restore the luteal phase or the pregnancy rate, both returning closer to normal after luteal support.
    2 context sentences
    Summary · context
    The luteal phase (LP) of patients receiving triptorelin 0.1 mg to trigger ovulation was studied.
    Summary · context
    Patients not pregnant in the first cycle with 0.1 mg were randomized into different groups for a second cycle: 0.1 mg again for patients who experienced a normal LP (group 1); patients affected with LP disorders were randomized into the following groups: 0.1 mg again (group 2); increasing dosage of…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with defective luteal phases, increased or repeated triptorelin doses did not restore pregnancy rates.

    In plain wordsIn patients with defective luteal phases, increased or repeated triptorelin doses did not restore pregnancy rates.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changePregnancy rate restoration
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.5 mg once or 0.1 mg three timesAs given in this study (human).

    Source sentences

    Summary
    In defective LP patients, increasing or repeating triptorelin doses did not restore the luteal phase or the pregnancy rate, both returning closer to normal after luteal support.
    2 context sentences
    Summary · context
    The luteal phase (LP) of patients receiving triptorelin 0.1 mg to trigger ovulation was studied.
    Summary · context
    Patients not pregnant in the first cycle with 0.1 mg were randomized into different groups for a second cycle: 0.1 mg again for patients who experienced a normal LP (group 1); patients affected with LP disorders were randomized into the following groups: 0.1 mg again (group 2); increasing dosage of…
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients undergoing triptorelin-triggered cycles, including cycles with progesterone or HCG support, ovulation occurred in all cycles.

    In plain wordsIn patients undergoing triptorelin-triggered cycles, including cycles with progesterone or HCG support, ovulation occurred in all cycles.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableOvulation
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.1 mg; 0.5 mg once or 0.1 mg three times in some second cyclesAs given in this study (human).

    Source sentences

    Summary
    Ovulation occurred in all cycles, but an inadequate LP was observed in 34.4% of the non-conceptional cycles.
    2 context sentences
    Summary · context
    The luteal phase (LP) of patients receiving triptorelin 0.1 mg to trigger ovulation was studied.
    Summary · context
    Patients not pregnant in the first cycle with 0.1 mg were randomized into different groups for a second cycle: 0.1 mg again for patients who experienced a normal LP (group 1); patients affected with LP disorders were randomized into the following groups: 0.1 mg again (group 2); increasing dosage of…
  4. 04HumanNon-randomized trialSafety outcome

    In patients receiving triptorelin, an inadequate luteal phase occurred in 34.4% of non-conceptional cycles.

    In plain wordsIn patients receiving triptorelin, an inadequate luteal phase occurred in 34.4% of cycles without conception.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableInadequate luteal phase
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.1 mgAs given in this study (human).

    Measurements

    Inadequate luteal phase
    34.4%
    non-conceptional cycles after triptorelin trigger

    Source sentences

    Summary
    Ovulation occurred in all cycles, but an inadequate LP was observed in 34.4% of the non-conceptional cycles.
    2 context sentences
    Summary · context
    The luteal phase (LP) of patients receiving triptorelin 0.1 mg to trigger ovulation was studied.
    Summary · context
    Patients not pregnant in the first cycle with 0.1 mg were randomized into different groups for a second cycle: 0.1 mg again for patients who experienced a normal LP (group 1); patients affected with LP disorders were randomized into the following groups: 0.1 mg again (group 2); increasing dosage of…
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients receiving triptorelin, repeated cycles with the same trigger retained the initial normal or defective luteal pattern.

    In plain wordsIn patients receiving triptorelin, repeated cycles with the same trigger retained the initial normal or defective luteal pattern.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeRepeated-cycle luteal pattern
    Study

    n: not reported in source

    Comparator
    First cycle with the same trigger
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.1 mgAs given in this study (human).

    Source sentences

    Summary
    Patients demonstrating a normal LP as well as those affected with luteal disorders in their first cycle showed the same luteal pattern in their consecutive cycles triggered in the same way.
    2 context sentences
    Summary · context
    The luteal phase (LP) of patients receiving triptorelin 0.1 mg to trigger ovulation was studied.
    Summary · context
    Patients not pregnant in the first cycle with 0.1 mg were randomized into different groups for a second cycle: 0.1 mg again for patients who experienced a normal LP (group 1); patients affected with LP disorders were randomized into the following groups: 0.1 mg again (group 2); increasing dosage of…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.